Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

A modified technique for mechanical isolation of stromal vascular fraction yields increased final product volume and high viable nucleated cells count.

Totlis T., Emfietzis PK., Niti A., Achlatis V., Vonk LA., Terzidis I.

Prospective Study on Osteoarthritis, published in J Exp Orthop (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Exp Orthop (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40718550
PMCID
PMC12296706
DOI
10.1002/jeo2.70378
Citations
1

Abstract (original English)

Purpose Purpose of the present study is to report a modified protocol for stromal vascular fraction (SVF) isolation from abdominal fat, analyse its cellular composition and gene expression profile, and verify the safety and feasibility of the harvesting-preparation technique and subsequent intra-articular knee injection. Methods The SVF was obtained after mechanical dissociation of the autologous harvested adipose tissue. It was combined with autologous platelet-rich plasma and subsequently intra-articularly injected into both knees of patients with osteoarthritis. Part of the SVF solution was used to analyse its cellular composition via flow cytometry and its gene expression profile via real-time polymerase chain reaction. Any postinjection complications were documented. Results Twenty-three patients (10 female; 62.4 ± 8.4 years old) were enrolled. Posttreatment adverse events were mild and spontaneously resolved. Patients needed 3.7 ± 1.3 days for their knee to feel the same as before the injection. No patient provided less than 60 mL of lipoaspirate. Per 1 mL of SVF the total amount of viable nucleated cells was 49.7 ± 22.9 × 10 6 on average, including 44.5 ± 23.2 × 10 6 CD90+/CD105+ adipose-derived stem cells, 0.54 ± 0.18 × 10 6 hematopoietic stem cells, 2.71 ± 1.18 × 10 6 pericytes and 1.88 ± 0.64 × 10 6 endothelial cells. The polymerase chain reaction analysis revealed th

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research